Skip to main contentAI and Advanced
/
LYKALABS · BSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
LY
BSE · Equity shares · Biotechnology & Drugs14.92 · 1.97%
Lyka Labs LYKALABS
NSE:INR 65.5
BSE:INR 82.45
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for LYKALABS
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 67.53
Day rangeINR 63.8 — INR 65.89
52-week rangeINR 44.49 — INR 121
Volume25,503
Market cap231.99
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)128.44
Net Income (INR Cr)-10.03
Rev Growth (5 Year %)8.29
Book Value24
EPS-2.81
Price/BV3.44Computed
Research path: Interpret Lyka Labs's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
LYKALABSLyka Labs1d · INR · BSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 174.54 | 176.21 | 156.86 |
| Other Liabilities Total | 4.7 | 1.8 | 2.83 |
| Accrued Expenses | 1.21 | 2.2 | 2.02 |
| Long Term Debt | 22.99 | 19.21 | 42.91 |
| Common Stock Total | 35.69 | 35.69 | 33.09 |
| Other Current Assets Total | 7.65 | 0.95 | 5.69 |
| Total Assets | 174.54 | 176.21 | 156.86 |
| Current Portof LT Debt/Capital Leases | 25.88 | 10.02 | 4.5 |
| Cash | 1.36 | 0.39 | 0.26 |
| Total Equity | 92.39 | 103.55 | 68.15 |
| Long Term Investments | 15.76 | 0.02 | 0.07 |
| Retained Earnings(Accumulated Deficit) | 56.7 | -120.12 | -119.06 |
| Total Common Shares Outstanding | 3.57 | 3.57 | 3.31 |
| Tangible Book Valueper Share Common Eq | 24 | 26.43 | 17 |
| Total Liabilities | 82.14 | 72.66 | 88.7 |
| Total Debt | 48.87 | 39.25 | 58.78 |
| Short Term Investments | 5.56 | 5.13 | 3.43 |
| Cashand Short Term Investments | 6.92 | 5.52 | 3.69 |
| Total Receivables Net | 35.08 | 46.66 | 31.45 |
| Deferred Income Tax | 2.12 | 4.29 | 3.83 |
| Accounts Receivable-Trade Net | 35.03 | 43.08 | 26.99 |
| Property/Plant/Equipment Total-Net | 82.26 | 77.1 | 68.84 |
| Minority Interest | -1.56 | 0.03 | 0.11 |
| Total Current Liabilities | 53.9 | 46.63 | 37.77 |
| Total Inventory | 13.63 | 12.47 | 9.57 |
| Total Preferred Shares Outstanding | 0.01 | 0.01 | 0.01 |
| Accounts Payable | 16.79 | 14.95 | 12.1 |
| Other Currentliabilities Total | 10.01 | 10.13 | 9.03 |
| Total Long Term Debt | 22.99 | 19.9 | 44.17 |
| Intangibles Net | 6.73 | 9.04 | 11.71 |
| Other Long Term Assets Total | 5.37 | 4.76 | 6.43 |
| Note Receivable-Long Term | 1.13 | 17.67 | 18.95 |
| Total Current Assets | 63.28 | 67.43 | 50.65 |
| Capital Lease Obligations | 0 | 0.69 | 1.26 |
| Accumulated Depreciation Total | Not available | -52.95 | -52.25 |
| Other Equity Total | Not available | -0.11 | -0.29 |
| Prepaid Expenses | Not available | 1.84 | 0.26 |
| Additional Paid-In Capital | Not available | 188.09 | 154.42 |
| Property/Plant/Equipment Total-Gross | Not available | 129.85 | 99.12 |
| Goodwill Net | Not available | 0.18 | 0.2 |
| Notes Payable/Short Term Debt | Not available | 9.33 | 10.11 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %-21.34
Margins
Operating Margin 12m-9.43
Operating Margin 5y Avg11.14
Net Profit Margin 12m-8.12
Net Profit Margin 5y3.03
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio1.81
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk56.55
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,938.25 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,375 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,972.65 | 1.68 L | 72.73 | — |
| Cipla | INR 1,406.45 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,119 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 58.45%
- FII
- 0.17%
- MF
- 0.01%
- Other
- 41.37%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Lyka Labs Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight - MarketsMojoMarket news · 21 Jul 2026, 10:26 am
Lyka Labs Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight MarketsMojo
Lyka Labs Annual Report FY2025-26: Consolidated Revenue Declines, Net Loss Widens on Exceptional Impairment Charge - scanx.tradeMarket news · 20 Jul 2026, 10:19 am
Lyka Labs Annual Report FY2025-26: Consolidated Revenue Declines, Net Loss Widens on Exceptional Impairment Charge scanx.trade
Lyka Labs to seek approval for ₹75 crore IPCA transactions at AGM - scanx.tradeMarket news · 18 Jul 2026, 1:11 am
Lyka Labs to seek approval for ₹75 crore IPCA transactions at AGM scanx.trade
Lyka Labs Posts Rs 10.58 Crore Loss in FY26, Impairment Hits Results - WhalesbookMarket news · 17 Jul 2026, 9:06 am
Lyka Labs Posts Rs 10.58 Crore Loss in FY26, Impairment Hits Results Whalesbook
Lyka Labs proposes ₹75 Crore RPT with Promoter IPCA Labs - WhalesbookMarket news · 17 Jul 2026, 9:01 am
Lyka Labs proposes ₹75 Crore RPT with Promoter IPCA Labs Whalesbook
Lyka Labs Ltd Locks at Upper Circuit With 2.8% Gain — Buyers Queue, Sellers Absent - MarketsMojoMarket news · 10 Jul 2026, 11:15 am
Lyka Labs Ltd Locks at Upper Circuit With 2.8% Gain — Buyers Queue, Sellers Absent MarketsMojo
Corporate actions
Events
- annual General MeetingAGM
- board MeetingsAudited Results
- board MeetingsTo consider other business matters.
- board MeetingsQuarterly Results
- board MeetingsTo consider other business matters.
- board MeetingsInter-alia, to conisder 1. To Approve Redemption of unlisted 1,08,570 10% Cumulative Redeemable Preference Shares of Rs.100/- each. 2. Other business matters.
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Lyka Labs
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Lyka Labs Limited is an India-based pharmaceutical company engaged in the development, manufacture and marketing of quality finished dosages. The Company manufactures pharmaceutical products such as Dry Powder, Liquid, Lyophilized Injections and External Preparations for several International Markets and the Domestic Market. The Company’s R&D is engaged in the development of new formulations and has developed several products in the categories, such as Injectables: Lyophilized Injection, Liquid Injections & Dry Powder Injections, and Topical Preparation: Ointment /Creams and Lotions. It offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, antifungal, anti-malarial, antibacterial, corticosteroid hormones and cephalosporins. The Company's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- LYKALABS
- BSE Code
- 500259
Questions
Stock FAQ
What is the symbol and ISIN of Lyka Labs?
Lyka Labs has the symbol LYKALABS and ISIN - INE933A01014.
What is the current price of Lyka Labs?
Lyka Labs is currently trading at INR 82.45.
What are the year high and year low of Lyka Labs?
Lyka Labs has a year high of INR 121.00 and a year low of INR 44.49.
What is the market capitalization of Lyka Labs?
Lyka Labs has a market capitalization of INR 231.99 crore.
What is the P/E ratio of Lyka Labs?
Lyka Labs has a P/E ratio of NA.
What is the dividend yield of Lyka Labs?
Lyka Labs has a dividend yield of 0.00%.
How is the financial performance of Lyka Labs based on revenue, net income, and EPS?
Lyka Labs has revenue of INR 128.44 crore, net income of INR -10.03 crore, and EPS of INR -2.82.
What is the book value of Lyka Labs?
Lyka Labs has a book value of INR 24.00.
What is the debt-to-equity ratio of Lyka Labs?
Lyka Labs has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Lyka Labs?
Lyka Labs has a price-to-book ratio of 3.44 and a price-to-sales ratio of 1.81.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.